You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 437 Optimised achilles VELOSTM process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
437 Optimised achilles VELOSTM process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Sassi M, Gomez S, Rologi E, et al
437 Optimised achilles VELOSTM process 2b manufacturing platform generates a significant dose boost of reactive CD8 and CD4 clonal neoantigen-reactive T cells for the treatment of solid cancer
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0437